Efficacy and safety of midostaurin in advanced systemic mastocytosis

Jason Gotlib, Hanneke C. Kluin-Nelemans, Tracy I. George, Cem Akin, Karl Sotlar, Olivier Hermine, Farrukh T. Awan, Elizabeth Hexner, Michael J. Mauro, David W. Sternberg, Matthieu Villeneuve, Alice Huntsman Labed, Eric J. Stanek, Karin Hartmann, Hans Peter Horny, Peter Valent, Andreas Reiter

Research output: Contribution to journalArticle

177 Scopus citations

Abstract

BACKGROUND: Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and lack effective treatment options. The multikinase inhibitor midostaurin inhibits KIT D816V, a primary driver of disease pathogenesis. METHODS: We conducted an open-label study of oral midostaurin at a dose of 100 mg twice daily in 116 patients, of whom 89 with mastocytosis-related organ damage were eligible for inclusion in the primary efficacy population; 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast-cell leukemia. The primary outcome was the best overall response. RESULTS: The overall response rate was 60% (95% confidence interval [CI], 49 to 70); 45% of the patients had a major response, which was defined as complete resolution of at least one type of mastocytosis-related organ damage. Response rates were similar regardless of the subtype of advanced systemic mastocytosis, KIT mutation status, or exposure to previous therapy. The median best percentage changes in bone marrow mast-cell burden and serum tryptase level were -59% and -58%, respectively. The median overall survival was 28.7 months, and the median progression-free survival was 14.1 months. Among the 16 patients with mast-cell leukemia, the median overall survival was 9.4 months (95% CI, 7.5 to not estimated). Dose reduction owing to toxic effects occurred in 56% of the patients; re-escalation to the starting dose was feasible in 32% of those patients. The most frequent adverse events were low-grade nausea, vomiting, and diarrhea. New or worsening grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in 24%, 41%, and 29% of the patients, respectively, mostly in those with preexisting cytopenias. CONCLUSIONS: In this open-label study, midostaurin showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal variant mast-cell leukemia.

Original languageEnglish (US)
Pages (from-to)2530-2541
Number of pages12
JournalNew England Journal of Medicine
Volume374
Issue number26
DOIs
StatePublished - Jun 30 2016
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Efficacy and safety of midostaurin in advanced systemic mastocytosis'. Together they form a unique fingerprint.

  • Cite this

    Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F. T., Hexner, E., Mauro, M. J., Sternberg, D. W., Villeneuve, M., Labed, A. H., Stanek, E. J., Hartmann, K., Horny, H. P., Valent, P., & Reiter, A. (2016). Efficacy and safety of midostaurin in advanced systemic mastocytosis. New England Journal of Medicine, 374(26), 2530-2541. https://doi.org/10.1056/NEJMoa1513098